Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus

被引:338
作者
Higgins, DL [1 ]
Chang, R [1 ]
Debabov, DV [1 ]
Leung, J [1 ]
Wu, T [1 ]
Krause, KA [1 ]
Sandvik, E [1 ]
Hubbard, JM [1 ]
Kaniga, K [1 ]
Schmidt, DE [1 ]
Gao, QF [1 ]
Cass, RT [1 ]
Karr, DE [1 ]
Benton, BM [1 ]
Humphrey, PP [1 ]
机构
[1] Theravance Inc, San Francisco, CA 94080 USA
关键词
D O I
10.1128/AAC.49.3.1127-1134.2005
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The emergence and spread of multidrug-resistant gram-positive bacteria represent a serious clinical problem. Telavancin is a novel lipoglycopeptide antibiotic that possesses rapid in vitro bactericidal activity against a broad spectrum of clinically relevant gram-positive pathogens. Here we demonstrate that telavancin's antibacterial activity derives from at least two mechanisms. As observed with vancomycin, telavancin inhibited late-stage peptidoglycan biosynthesis in a substrate-dependent fashion and bound the cell wall, as it did the lipid II surrogate tripeptide N,N'-diacetyl-L-lysinyl-D-alanyl-D-alanine, with high affinity. Telavancin also perturbed bacterial cell membrane potential and permeability. In methicillin-resistant Staphylococcus aureus, telavancin caused rapid, concentration-dependent depolarization of the plasma membrane, increases in permeability, and leakage of cellular ATP and K+. The timing of these changes correlated with rapid, concentration-dependent loss of bacterial viability, suggesting that the early bactericidal activity of telavancin results from dissipation of cell membrane potential and an increase in membrane permeability. Binding and cell fractionation studies provided direct evidence for an interaction of telavancin with the bacterial cell membrane; stronger binding interactions were observed with the bacterial cell wall and cell membrane relative to vancomycin. We suggest that this multifunctional mechanism of action confers advantageous antibacterial properties.
引用
收藏
页码:1127 / 1134
页数:8
相关论文
共 58 条
[31]   Comparative in vitro activity of telavancin (TD-6424), a rapidly bactericidal, concentration-dependent anti-infective with multiple mechanisms of action against Gram-positive bacteria [J].
King, A ;
Phillips, I ;
Kaniga, K .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2004, 53 (05) :797-803
[32]  
KOHLRAUSCH U, 1991, FEMS MICROBIOL LETT, V78, P253
[33]   Hydrophobic vancomycin derivatives with improved ADME properties: Discovery of telavancin (TD-6424) [J].
Leadbetter, MR ;
Adams, SM ;
Bazzini, B ;
Fatheree, PR ;
Karr, DE ;
Krause, KM ;
Lam, BMT ;
Linsell, MS ;
Nodwell, MB ;
Pace, JL ;
Quast, K ;
Shaw, JP ;
Soriano, E ;
Trapp, SG ;
Villena, JD ;
Wu, TX ;
Christensen, BG ;
Judice, JK .
JOURNAL OF ANTIBIOTICS, 2004, 57 (05) :326-336
[34]   GLYCOPEPTIDE ANTIBIOTIC-ACTIVITY AND THE POSSIBLE ROLE OF DIMERIZATION - A MODEL FOR BIOLOGICAL SIGNALING [J].
MACKAY, JP ;
GERHARD, U ;
BEAUREGARD, DA ;
WESTWELL, MS ;
SEARLE, MS ;
WILLIAMS, DH .
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 1994, 116 (11) :4581-4590
[35]   Glycopeptide derivatives [J].
Malabarba, A ;
Ciabatti, R .
CURRENT MEDICINAL CHEMISTRY, 2001, 8 (14) :1759-1773
[36]  
Malabarba A, 1997, MED RES REV, V17, P69, DOI 10.1002/(SICI)1098-1128(199701)17:1<69::AID-MED3>3.0.CO
[37]  
2-R
[38]   SYNTHESIS AND ANTIBACTERIAL EVALUATION OF N-ALKYL VANCOMYCINS [J].
NAGARAJAN, R ;
SCHABEL, AA ;
OCCOLOWITZ, JL ;
COUNTER, FT ;
OTT, JL ;
FELTYDUCKWORTH, AM .
JOURNAL OF ANTIBIOTICS, 1989, 42 (01) :63-72
[39]  
*NAT COMM CLIN LAB, 2002, METH DIL ANT SUSC TE
[40]   Semisynthetic glycopeptide antibiotics derived from LY264826 active against vancomycin-resistant enterococci [J].
Nicas, TI ;
Mullen, DL ;
Flokowitsch, JE ;
Preston, DA ;
Snyder, NJ ;
Zweifel, MJ ;
Wilkie, SC ;
Rodriguez, MJ ;
Thompson, RC ;
Cooper, RDG .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (09) :2194-2199